Drug intelligence / Profile preview

SRNA-002

Development stage: Preclinical
Lead developer: Serna Bio
Modality: Small Molecules
Administration: Oral

Overview

SRNA-002 is a preclinical-stage, RNA-targeted small molecule therapeutic candidate being developed by Serna Bio. The program is designed to modulate RNA function (such as regulating translation or splicing) to control protein expression. Both the specific biological target and the therapeutic indication for SRNA-002 remain undisclosed.

Beyond the preview

Go deeper on SRNA-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRNA-002.

Explore the full profile